Hollebecque et al. [18] evaluated the efficacy of LY3300054 (anti-PD-L1 antibody) alone or in combination with LY3321367 (anti-TIM-3 antibody) in 82 patients with MSI-H/dMMR advanced solid tumors, including 14 patients with endometrial cancer. This evidence concerns the gene CD274 and endometrial cancer.